Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 16;12(1):2158006. doi: 10.1080/2162402X.2022.2158006

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 6. — Abrogation of ADAM12 sensitizes T11 tumors to anti-PD1/anti-CTLA4 therapy. (a) Diagram of the treatment. BALB/c mice were orthotopically injected with A12-KO or control T11 cells (2x10⁴ cells/per injection). When tumor sizes reached ~10-20 mm², mice were randomized and injected intraperitoneally with anti-PD1/anti-CTLA4 antibodies or with isotope control antibodies bi-weekly or remained untreated. (b) The effect of anti-PD1/anti-CTLA4 antibodies on T11 tumor growth. (c) The effect of isotope control antibodies on the growth of A12-KO (g1) tumors. (d) Tumor growth rates and progression free survival of A12-KO (g1) tumors treated with anti-PD1/anti-CTLA4 antibodies versus untreated tumors. (e) Tumor growth rates and progression free survival of A12-KO (g2) tumors treated with anti-PD1/anti-CTLA4 antibodies versus untreated tumors. In d and e, progression was defined as a 20% increase in tumor diameter, or 1.44-fold increase in tumor area.